Advertisement
Organisation › Details
RA Capital Management L.P.
RA Capital is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing medicines, medical devices and diagnostics. The flexibility of its strategy allows RA capital to provide seed funding to startups and to lead private IPO, and follow-on financings for its portfolio companies, enabling management teams to drive value creation from inception through commercialization. At RA Capital’s core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes to put data into context, identify breakthroughs, and originate conviction in new ideas. TechAtlas provides market intelligence, technical diligence, and other resources to both our internal investment team and our portfolio companies. *
Start | 2001-01-01 established | |
Industry | private equity | |
Industry 2 | LIFE SCIENCES | |
Person | Resnick, Joshua (Josh) (RA Capital 202007 Managing DIrector) | |
Region | Boston, MA | |
Country | United States (USA) | |
Street | 200 Berkeley Street 18th Floor | |
City | 02116 Boston, MA | |
Tel | +1-617-778-2500 | |
Address record changed: 2021-10-13 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Alentis Therapeutics AG. (4/13/23). "Press Release: Alentis Therapeutics Closes $105 Million Series C Funding to Advance Transformational Medicines for Claudin-1". Basel. | ||
Record changed: 2024-08-17 |
Advertisement
More documents for RA Capital Management L.P.
- [1] IDRx, Inc.. (8/7/24). "Press Release: IDRx Announces $120 Million Series B Financing to Advance Potential Best-in-class New Treatment for Gastrointestinal Stromal Tumor (GIST)". Plymouth, MA....
- [2] Capstan Therapeutics, Inc.. (3/20/24). "Press Release: Capstan Therapeutics Announces $175M Oversubscribed Series B Financing". San Diego, CA....
- [3] PepGen, Inc.. (8/5/21). "Press Release: PepGen Announces Closing of $112.5 Million Crossover Financing to Advance Transformative Therapies for Neuromuscular Diseases". Boston, MA....
- [4] Alchemab Therapeutics Ltd.. (4/15/21). "Press Release: Alchemab Raises £60 Million ($82 Million) in Series A Financing to Advance Novel Platform for Identifying Disease-modifying Antibody Therapeutics". Cambridge....
- [5] Metagenomi Inc.. (4/7/21). "Press Release: Metagenomi Extends Series A Financing from RA Capital and Welcomes Andrew Levin to Its Board of Directors". Emeryville, CA....
- [6] Nucleix. (4/7/21). "Press Release: Nucleix Secures $55 Million Funding Led by RA Capital Management and Additional Prominent Life Science Investors to Advance Lung EpiCheck® for Early Detection of Lung Cancer". San Diego, CA & Rehovot....
- [7] Eliem Therapeutics, Inc.. (3/25/21). "Press Release: Eliem Therapeutics Emerges from Stealth with $80 Million Invested to Progress Multiple Clinical Stage Assets Targeting Neuronal Excitability Disorders". Seattle, WA & Cambrigde....
- [8] PepGen Ltd.. (2/4/21). "Press Release: PepGen Announces Appointment of James McArthur, Ph.D., as President and Chief Executive Officer". Boston, MA & Oxford....
- [9] DiCE Molecules SV, Inc.. (1/8/21). "Press Release: DiCE Molecules Announces $80 Million Series C Financing. Jake Simson, Ph.D., Joins Board of Directors". South San Francisco, CA....
- [10] PepGen Ltd.. (12/9/20). "Press Release: PepGen Raises $45M Series A". Boston, MA & Oxford....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top